This week: Good news from Caledonia Mining, CyanConnode, Ferro-Alloy Resources, Burberry and AstraZeneca

Business News

Caledonia Mining Corporation plc (LON:CMCL) reported a record quarterly production this week of almost 19,000 ounces. Revenue in the Quarter was 32 per cent higher than in Q3 2020 due to a 42 per cent increase in the quantity of gold produced and sold offset by a 7 per cent decrease in the average realised gold price.

CyanConnode Holdings plc (LON:CYAN), a world leader in Narrowband Radio Frequency (RF) Smart Mesh Networks, announced this week that it has won the Cambridge Wireless Best Connector Business” Award.

John Cronin, CyanConnode Executive Chairman, commented: “This award only strengthens our core belief of not just meeting customer expectations but exceeding them. CyanConnode being lead technology innovation player will continue raising the bar for quality Smart Metering deployment.”

Ferro-Alloy Resources Limited (LON:FAR), the vanadium producer and developer of the large Balasausqandiq vanadium deposit in Southern Kazakhstan, announced it has now made its first commercial sale of ferro-molybdenum and also completed testing of the production of ferro-vanadium.

Nick Bridgen, Ferro-Alloy Resources CEO, commented: “These are two important steps towards maximising the value we get from our exciting operation, and further demonstrates our growing technical expertise.”

Sativa Wellness Group Inc. (AQSE:SWEL) has announced its second quarterly profit in Q3 2021 with Q3 2021 Revenue 977% higher vs comparative quarter 2020.

Geremy Thomas, Sativa Wellness Executive Chairman, said; “I am so pleased the significant growth of the business accelerated through Q3. We are exceeding expectations and the strategy introduced earlier in the year continues to validate our mission to deliver to consumers and partners a diverse health and wellness company.”

Burberry Group plc (LON:BRBY) announced in its interim results for 26 weeks ended 25 September 2021 that H1 FY22 revenues were back at pre COVID-19 levels.

Burberry Chairman Gerry Murphy said, ““We have made strong progress in the half. Full-price sales are growing at a double-digit percentage, driving margin expansion and strong free cash generation.”

AstraZeneca PLC (LON:AZN) announced in its year to date and Q3 2021 results that total revenue, including Alexion from 21 July 2021, was $25,406m, representing growth of 32% and total revenue in the third quarter increased by 50%.

Pascal Soriot, Chief Executive Officer, commented:

“AstraZeneca’s scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery, with eight positive late-stage readouts across seven medicines since June, including our long acting antibody combination showing promise in both prevention and treatment of COVID-19.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ferro-Alloy Resources targets additional revenue from carbon black substitute

Ferro-Alloy Resources is targeting additional revenue at Balasausqandiq from a carbon-rich by-product with potential use as a carbon black substitute.

CyanConnode subsidiary supports Goa smart meter rollout with staff training

DigiSmart Networks has trained more than 250 Goa Electricity officials to support system use, field operations and complaint handling during the smart meter rollout.

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival.

Ferro-Alloy Resources points to the scale of vanadium demand from grid storage

Ferro-Alloy Resources highlights the scale of vanadium demand that could come from major grid storage projects as Invinity advances design work on a gigawatt-hour vanadium flow battery.

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options.

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials.

Search